We are actively engaged in studies linking clinical outcomes to pathophysiology, also on a molecular basis. A good example is that based on outcomes from omics studies, we investigate the functionality of genes and proteins in lung diseases using molecular approaches:
- in cells and tissues from patients,
- in cell lines
- and in animal models.
We also explore intracellular and intercellular pathways for
- tissue repair,
- disease development, progression and remission,
- exploration of novel drug targets.
We use in vivo and in vitro models, including complex disease models such as organoids, lung hydrogels and organ-on-chip models, to unravel mechanisms of disease and novel drug targets. Drug targets identified as such are potential new starting points for therapeutics, which we develop in collaboration with different partners, for example with the department of Pharmacy, or with Biotech and Pharmaceutical industry.